{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:55:06Z","timestamp":1789152906912,"version":"build-2803163510"},"reference-count":68,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"crossref","award":["R01 AG061558"],"award-info":[{"award-number":["R01 AG061558"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Given the multi-faceted nature of cancer cachexia, a combination of pharmacologic and supportive measures such as exercise and nutrition seems intuitive to most clinicians. Clinical trials have also suggested that a multimodal approach to cancer cachexia (CC) is feasible and potentially effective. However, past trials have been limited by medications that were partially effective or had the potential for serious adverse events such as thromboembolism. We review new agents that have demonstrated efficacy in phase II trials or are involved in multi-center phase III studies. The advent of several recent phase II studies indicate that consistently effective, well-tolerated medications may soon be available for CC. These new agents target several mechanisms involved in CC, including food aversion, catabolism, and decreased anabolism. Several multi-center studies are expected to be actively recruiting this year. If these agents prove to be effective, individualized treatment may be possible, guided by individuals\u2019 phenotype and\/or clinical biomarkers. Future research should also determine whether combination therapy (pharmacologic and\/or non-pharmacologic) produces additive or synergistic benefits.<\/jats:p>","DOI":"10.3390\/cancers18040649","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:22:46Z","timestamp":1771320166000},"page":"649","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of New Agents and Supportive Care in a Multimodal Approach to Cancer Cachexia"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1245-6307","authenticated-orcid":false,"given":"Egidio","family":"Del Fabbro","sequence":"first","affiliation":[{"name":"Division of Palliative Medicine, Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-222X","authenticated-orcid":false,"given":"Sudeep","family":"Pandey","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Palliative Care, Virginia Commonwealth University, Richmond, VA 23284, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100282","DOI":"10.1016\/j.advnut.2024.100282","article-title":"Prevalence of and Survival with Cachexia among Patients with Cancer: A Systematic Review and Meta-Analysis","volume":"15","author":"Takaoka","year":"2024","journal-title":"Adv. Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jcsm.12402","article-title":"Orphan disease status of cancer cachexia in the USA and in the European Union: A systematic review","volume":"10","author":"Anker","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1634\/theoncologist.2009-0153","article-title":"Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia","volume":"15","author":"Mantovani","year":"2010","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e70128","DOI":"10.1002\/jcsm.70128","article-title":"Cachexia and Wasting in Chronic Illness: Regulatory and Clinical Trial Update","volume":"16","author":"Fioretti","year":"2025","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-06-2720","article-title":"Insulin treatment in cancer cachexia: Effects on survival, metabolism, and physical functioning","volume":"13","author":"Lundholm","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.20.01254","article-title":"Early Interdisciplinary Supportive Care in Patients with Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial","volume":"39","author":"Lu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_7","first-page":"18","article-title":"A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia","volume":"6","author":"Wiedenmann","year":"2008","journal-title":"J. Support. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1\u03b1 in refractory cancers: An open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1200\/JCO.23.01965","article-title":"Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine with or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia","volume":"43","author":"Chen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wischhusen, J., Melero, I., and Fridman, W.H. (2020). Growth\/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00951"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s11357-021-00359-5","article-title":"Longitudinal course of GDF15 levels before acute hospitalization and death in the general population","volume":"43","author":"Tavenier","year":"2021","journal-title":"GeroScience"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"bnaa007","DOI":"10.1210\/endrev\/bnaa007","article-title":"GDF15: A Hormone Conveying Somatic Distress to the Brain","volume":"41","author":"Lockhart","year":"2020","journal-title":"Endocr. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","article-title":"GDF15 mediates the effects of metformin on body weight and energy balance","volume":"578","author":"Coll","year":"2019","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jcsm.12033","article-title":"Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients","volume":"6","author":"Lerner","year":"2015","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/jcmm.12830","article-title":"Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer","volume":"20","author":"Li","year":"2016","journal-title":"J. Cell. Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the Treatment of Cancer Cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","article-title":"Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours","volume":"637","author":"Melero","year":"2025","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s11914-020-00628-w","article-title":"Sex Differences in Cancer Cachexia","volume":"18","author":"Zhong","year":"2020","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15889","article-title":"Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma","volume":"186","author":"Burkart","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Satari, S., Mota, I.N.R., Silva, A.C.L., Brito, H.O., Oliveira, P.A., Gil da Costa, R.M., and Medeiros, R. (2025). Hallmarks of Cancer Cachexia: Sexual Dimorphism in Related Pathways. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26093952"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1136\/bmjspcare-2019-002176","article-title":"Cachexia is associated with depression, anxiety and quality of life in cancer patients","volume":"13","author":"Sun","year":"2020","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jpainsymman.2010.06.021","article-title":"Association between serum cortisol and testosterone levels, opioid therapy, and symptom distress in patients with advanced cancer","volume":"41","author":"Dev","year":"2011","journal-title":"J. Pain Symptom Manag."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1093\/oncolo\/oyae024","article-title":"Anticancer drugs-related hypogonadism in male patients with advanced cancers on active treatment: A systematic review","volume":"29","author":"Massa","year":"2024","journal-title":"Oncologist"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ekedahl, H., Isaksson, S., St\u00e5hl, O., Bogefors, K., Romerius, P., Eberhard, J., and Giwercman, A. (2022). Low-grade inflammation in survivors of childhood cancer and testicular cancer and its association with hypogonadism and metabolic risk factors. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09253-5"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sun, T., Peng, R., Sun, X., and Li, Y. (2021). Associations between sex hormones and circulating growth differentiation factor-15 in male patients with major depressive disorder. Brain Sci., 11.","DOI":"10.3390\/brainsci11121612"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Walsh, J.S., Marshall, H., Smith, I.L., Greenfield, D.M., Swain, J., Best, E., Ashton, J., Brown, J.M., Huddart, R., and Coleman, R.E. (2019). Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. PLoS Med., 16.","DOI":"10.1371\/journal.pmed.1002960"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/jcsm.12295","article-title":"A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women","volume":"9","author":"Wright","year":"2018","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bmt.1703421","article-title":"Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies","volume":"29","author":"Chatterjee","year":"2002","journal-title":"Bone Marrow Transplant."},{"key":"ref_29","first-page":"2599","article-title":"Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: A preliminary double-blind placebo-controlled trial","volume":"21","author":"Garcia","year":"2013","journal-title":"Support. Care Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"216","DOI":"10.14309\/ajg.0000000000000446","article-title":"Circulating sex hormone levels and risk of esophageal adenocarcinoma in a prospective study in men","volume":"115","author":"Xie","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1365-2265.2010.03804.x","article-title":"Accuracy of calculated free testosterone formulae in men","volume":"73","author":"Ly","year":"2010","journal-title":"Clin. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103500","DOI":"10.1016\/j.eclinm.2025.103500","article-title":"Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: A multicentre, open-label, randomised controlled trial","volume":"88","author":"Yamamoto","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1177\/10781552231189864","article-title":"The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Rezaei","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/jcsm.12191","article-title":"Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: Results from the COPERNICUS trial","volume":"8","author":"Clark","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMoa010342","article-title":"Reversal of catabolism by beta-blockade after severe burns","volume":"345","author":"Herndon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13054-015-0913-x","article-title":"Propranolol attenuates hemorrhage and accelerates wound healing in severely burned adults","volume":"19","author":"Ali","year":"2015","journal-title":"Crit. Care"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0959-8049(99)00273-7","article-title":"Beta-adrenoceptor activity and resting energy metabolism in weight-losing cancer patients","volume":"36","author":"Hyltander","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/01635581.2024.2411763","article-title":"International survey on consensus definition on nutrition impact symptoms in patients with cancer","volume":"77","author":"Amano","year":"2024","journal-title":"Nutr. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.oraloncology.2014.06.009","article-title":"Nutrition impact symptoms in a population cohort of head and neck cancer patients: Multivariate regression analysis of symptoms on oral intake, weight loss and survival","volume":"50","author":"Farhangfar","year":"2014","journal-title":"Oral Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Anandavadivelan, P., Martin, L., Dj\u00e4rv, T., Johar, A., and Lagergren, P. (2018). Nutrition impact symptoms are prognostic of quality of life and mortality after surgery for oesophageal cancer. Cancers, 10.","DOI":"10.3390\/cancers10090318"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1089\/jpm.2011.0098","article-title":"Clinical outcomes and contributors to weight loss in a cancer cachexia clinic","volume":"14","author":"Hui","year":"2011","journal-title":"J. Palliat. Med."},{"key":"ref_44","first-page":"55","article-title":"Mapping the impact of malnutrition as defined by the Global Leadership Initiative on Malnutrition and nutrition impact symptoms on the possibility of returning to work after treatment for head and neck cancer","volume":"32","author":"Einarsson","year":"2023","journal-title":"Support. Care Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clnesp.2024.02.027","article-title":"Associations of nutrition impact symptoms with dietary intake and eating-related distress in patients with advanced cancer","volume":"60","author":"Amano","year":"2024","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/cncr.32437","article-title":"High prevalence of malnutrition and nutrition impact symptoms in older patients with cancer: Results of a Brazilian multicenter study","volume":"126","author":"Martucci","year":"2020","journal-title":"Cancer"},{"key":"ref_47","first-page":"83","article-title":"The prevalence of nutrition impact symptoms and their relationship to quality of life and clinical outcomes in medical oncology patients","volume":"17","author":"Tong","year":"2008","journal-title":"Support. Care Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Khorasanchi, A., Nemani, S., Pandey, S., and Del Fabbro, E. (2022). Managing nutrition impact symptoms in cancer cachexia: A case series and mini review. Front. Nutr., 9.","DOI":"10.3389\/fnut.2022.831934"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_50","first-page":"8097","article-title":"MASCC antiemetics in advanced cancer updated guideline","volume":"29","author":"Davis","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1200\/JCO.20.00611","article-title":"Management of cancer cachexia: ASCO guideline","volume":"38","author":"Roeland","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.22.01997","article-title":"Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer","volume":"41","author":"Sandhya","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"385","DOI":"10.6004\/jnccn.2025.7033","article-title":"Olanzapine for anorexia in patients with incurable cancer and cachexia (OlAnCa): A double-blind, placebo-controlled, randomized clinical trial","volume":"23","author":"Othman","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_54","first-page":"2371","article-title":"Combined exercise and nutritional rehabilitation in outpatients with incurable cancer: A systematic review","volume":"27","author":"Hall","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_55","first-page":"7111","article-title":"The effect of exercise and nutrition interventions on physical functioning in patients undergoing haematopoietic stem cell transplantation: A systematic review and meta-analysis","volume":"29","author":"Prins","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients","volume":"36","author":"Arends","year":"2017","journal-title":"Clin. Nutr."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Dingemans, A.M., van Walree, N., Schramel, F., Soud, M.Y., Baltru\u0161kevi\u010dien\u0117, E., Lybaert, W., Veldhorst, M., van den Berg, C.A., and Kaasa, S. (2023). High protein oral nutritional supplements enable the majority of cancer patients to meet protein intake recommendations during systemic anti-cancer treatment: A randomised controlled parallel-group study. Nutrients, 15.","DOI":"10.3390\/nu15245030"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clnu.2016.12.012","article-title":"Defining the role of dietary intake in determining weight change in patients with cancer cachexia","volume":"37","author":"Nasrah","year":"2018","journal-title":"Clin. Nutr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"151803","DOI":"10.1016\/j.soncn.2024.151803","article-title":"Nonpharmacological management of cancer-related cachexia: A systematic review","volume":"41","author":"Constantina","year":"2025","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Braha, A., Albai, A., Timar, B., Negru, \u0218., Sorin, S., Roman, D., and Popovici, D. (2022). Nutritional interventions to improve cachexia outcomes in cancer\u2014A systematic review. Medicina, 58.","DOI":"10.3390\/medicina58070966"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.clnu.2016.06.022","article-title":"Effectiveness and efficacy of nutritional therapy: A systematic review following Cochrane methodology","volume":"36","author":"Muscaritoli","year":"2017","journal-title":"Clin. Nutr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1016\/j.clnu.2020.02.021","article-title":"Home artificial nutrition in palliative care cancer patients: Impact on survival and performance status","volume":"39","author":"Ruggeri","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/spcare-2024-005244","article-title":"Enteral and parenteral nutrition in patients with cancer: Complication rates compared\u2014Updated systematic review and meta-analysis","volume":"15","author":"Chow","year":"2025","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e843","DOI":"10.1634\/theoncologist.2019-0856","article-title":"Impact on health-related quality of life of parenteral nutrition for patients with advanced cancer cachexia: Results from a randomized controlled trial","volume":"25","author":"Bouleuc","year":"2020","journal-title":"Oncologist"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41430-025-01640-y","article-title":"Comparative clinical outcomes of home parenteral nutrition in adults with gastrointestinal or gynecologic cancers versus non-cancer patients: A prospective cohort study using propensity score matching from the Canadian HPN registry","volume":"79","author":"Unhapipatpong","year":"2025","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/nutrit\/nux026","article-title":"Challenges in conducting clinical nutrition research","volume":"75","author":"Weaver","year":"2017","journal-title":"Nutr. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/jamaoncol.2025.4560","article-title":"Semaglutide and tirzepatide prescribing for obesity in patients with preexisting comorbid cancers","volume":"12","author":"Kim","year":"2026","journal-title":"JAMA Oncol."},{"key":"ref_68","first-page":"CD015749","article-title":"Multimodal interventions for cachexia management","volume":"3","author":"Reid","year":"2025","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/649\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:17:01Z","timestamp":1771478221000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":68,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18040649"],"URL":"https:\/\/doi.org\/10.3390\/cancers18040649","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}